Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3701-3709

  Cai, Weijing ^a   Lin, Dongmei ^b   Wu, Chunyan ^a   Li, Xuefei ^a   Zhao, Chao ^a   Zheng, Limou ^c   Chuai, Shannon ^d   Fei, Ke ^a   Zhou, Caicun ^a   Hirsch, Fred R ^e  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Amsterdam   (China)

^c XIAMEN UNIVERSITY   (China)

^d Burning Rock Biotech ^*  (China)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ANAPLASTIC LYMPHOMA KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ALK GENE; ARTICLE; CANCER GENETICS; CANCER GROWTH; CONTROLLED STUDY; GENE; GENE FUSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INTRATUMORAL HETEROGENEITY; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PRIMARY TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; ADENOCARCINOMA; ADULT; AGED; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LASER CAPTURE MICRODISSECTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84947461588     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.8293     Document Type: Article

References (30)

1. Geyer FC, Weigelt B, Natrajan R, et al: Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 220:562-573, 2010
2. Anderson K, Lutz C, van Delft FW, et al: Genetic variegation of clonal architecture and propagating cells in leukemia. Nature 469:356-361, 2011
3. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
4. Wu X, Northcott PA, Dubuc A, et al: Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482:529-533, 2012
5. Bai H, Wang Z, Chen K, et al: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30:3077-3083, 2012
6. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005, 2010
7. Navin N, Krasnitz A, Rodgers L, et al: Inferring tumor progression from genomic heterogeneity. Genome Res 20:68-80, 2010
8. Navin N, Kendall J, Troge J, et al: Tumour evolution inferred by single-cell sequencing. Nature 472:90-94, 2011
9. Shimosato Y: Histological typing of lung and pleural tumors (3rd edition, 1999): Malignant epithelial tumors [in Japanese]. Nihon Rinsho 60:123-131, 2002 (suppl 5)
10. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13-17, 2008
11. Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223, 2009
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
13. Jokoji R, Yamasaki T, Minami S, et al: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63:1066-1070, 2010
14. Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17:889-897, 2010
15. Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35:1226-1234, 2011
16. Pan Y, Zhang Y, Li Y, et al: ALK, ROS1, and RET fusions in 1, 139 lung adenocarcinomas: A comprehensive study of common and fusion patternspecific clinicopathologic, histologic, and cytologic features. Lung Cancer 84:121-126, 2014
17. Yap TA, Gerlinger M, Futreal PA, et al: Intratumor heterogeneity: Seeing the wood for the trees. Sci Transl Med 4:127ps10, 2012
18. Cai W, Su C, Li X, et al: KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 119:1486-1494, 2013
19. Cai W, Li X, Su C, et al: ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol 24:1822-1827, 2013
20. Cai W, Li W, Ren S, et al: Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: A case report. J Thorac Oncol 9:e43-e46, 2014
21. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
22. Wynes MW, Sholl LM, Dietel M, et al: An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9:631-638, 2014
23. Yang JJ, Zhang XC, Su J, et al: Lung cancers with concomitant EGFR mutations and ALK rearrangements: Diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 20:1383-1392, 2014
24. Tomonaga N, Nakamura Y, Yamaguchi H, et al: Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer 14:521-526, 2013
25. Govindan R, Ding L, Griffith M, et al: Genomic landscape of non-small-cell lung cancer in smokers and never-smokers. Cell 150:1121-1134, 2012
26. Chiari R, Duranti S, Ludovini V, et al: Longterm response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. J Clin Oncol 32:e30-e32, 2014
27. Doebele RC, Pilling AB, Aisner DL, et al: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer. Clin Cancer Res 18:1472-1482, 2012
28. Bourzac K: Biology: Three known unknowns. Nature 509:S69-S671, 2014
29. Greaves M, Maley CC: Clonal evolution in cancer. Nature 481:306-313, 2012
30. Marusyk A, Almendro V, Polyak K: Intratumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 12:323-334, 2012